Overview

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-19

Target enrollment:

Participant gender:

Summary

This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.

Phase:

PHASE2

Details

Lead Sponsor:

AstraZeneca

Treatments:

semaglutide